Evercore ISI Begins Coverage of Beam Therapeutics With Bullish Outlook

Evercore ISI initiates coverage of Beam Therapeutics (BEAM) with an Outperform rating and $35 price target, citing promising early data for BEAM-302 in treating AATD and highlighting key data expected in Q1 2026.